Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CWI1-2 is a potent IGF2BP2 inhibitor that inhibits its interaction with M6A-modified target transcripts by binding IGF2BP2. CWI1-2 has anti-leukemic activity and can induce apoptosis and differentiation.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | お問い合わせ | ¥ 10,000 |
5 mg | お問い合わせ | ¥ 24,000 |
10 mg | お問い合わせ | ¥ 41,000 |
25 mg | お問い合わせ | ¥ 91,000 |
50 mg | お問い合わせ | ¥ 148,000 |
100 mg | お問い合わせ | ¥ 226,500 |
500 mg | お問い合わせ | ¥ 454,500 |
説明 | CWI1-2 is a potent IGF2BP2 inhibitor that inhibits its interaction with M6A-modified target transcripts by binding IGF2BP2. CWI1-2 has anti-leukemic activity and can induce apoptosis and differentiation. |
In vitro | CWI1-2 demonstrates excellent anti-leukemia efficacy in a concentration range of 0-1 μM for 24 hours[1]. |
In vivo | Administered intravenously at 5 mg/kg once daily for 7-10 days, CWI1-2 significantly delays the onset of leukemia and extends the survival time in BMT (bone marrow transplantation) recipient B6.SJL (CD45.1) mice, with no apparent impact on body weight[1]. |
分子量 | 519.77 |
分子式 | C22H17Cl3N6O3 |
CAS No. | 2408590-36-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (173.15 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CWI1-2 2408590-36-1 Apoptosis CWI12 Inhibitor inhibitor inhibit